Clinical trial
Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
NCT00299988 · Weill Medical College of Cornell University, Other · Terminated
Key facts
| NCT number | NCT00299988 |
|---|---|
| Title | Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease |
| Official title | A Placebo-controlled, Randomized, Double-Blind Phase II Clinical Study of Gammagard Intravenous Immunoglobulin (IVIg) for Treatment of Mild to Moderate Alzheimer's Disease |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | Baxter BioScience Industry National Institutes of Health (NIH) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug, Other |
| Interventions | Intravenous Immunoglobulin, Placebo |
| Enrollment | 24 |
| Start date | Feb 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Apr 1, 2010 |
| First posted | Mar 7, 2006 |
| Last update posted | Dec 11, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: